Business Wire

SentryOne Introduces Database Monitoring Edition Targeted to Smaller Environments

Share

SentryOne launched SQL Sentry Essentials, a new edition of the company’s top-rated SQL Sentry database monitoring product that provides core monitoring capabilities for up to five database targets at $995 per targeted SQL Server instance.

SQL Sentry Essentials includes the most frequently used features for monitoring, diagnosing, and optimizing SQL Server performance. This new edition is ideal for small and medium companies as well as larger organizations that need to monitor specific data systems within their environment.

“SQL Sentry Essentials is a perfect choice when you need to deploy SQL Server performance management at a small scale, or if you need enterprise capabilities but aren’t ready to build the case for an investment in a larger database performance management solution,” said Jason Hall, SentryOne VP of Product Management. “This new edition gives you the crucial information you need to get to the root of your SQL Server performance problems.”

SentryOne introduced SQL Sentry Essentials to meet the industry need for a monitoring solution that provides powerful core monitoring capabilities but excludes advanced features valued by larger enterprises.

“Everyone needs to monitor their databases, but not everyone needs all the advanced features of our flagship product, SQL Sentry,” said Andy Mallon, SentryOne Product Manager. “We’ve distilled the feature list down to the most essential monitoring capabilities, now available as SQL Sentry Essentials. This new edition is a powerful, capable solution for companies who need to monitor up to five instances, all at a very attractive price.”

SQL Sentry Essentials includes five of the most frequently used SQL Sentry features, helping data pros view essential real-time performance metrics, identify high-impact queries that are slowing performance, use proactive notifications to prevent problems, analyze SQL Server blocking and deadlocks, and view Windows resource metrics.

SentryOne customer David Klee, Heraflux Technologies Founder and Chief Architect, said that one of the features included in SQL Sentry Essentials, the Performance Analysis Dashboard, gives actionable information that helps data pros quickly identify and address problems.

“Lots of other utilities provide 'pretty' dashboards that do not provide much meaning,” Klee said. “SentryOne gives you a dashboard that presents vital performance statistics. Anything unusual jumps out at you and helps you refine how you approach that server.”

SQL Sentry Essentials is priced at US$995 per license, which can be applied to one targeted SQL Server instance, plus US$199 for annual maintenance (first year required). Subscription pricing is available at US$50 monthly (annual commitment required).

For more information, visit sentryone.com/sqlsentry-essentials.

About SentryOne
SentryOne empowers Microsoft data professionals to build, test, document, and monitor SQL Server, Azure SQL Database, and the Microsoft Data Platform. We help companies accelerate performance across the data lifecycle with unmatched scalability, best-in-industry customer support, and the most powerful data performance management capabilities available. Our team includes a core group of Microsoft MVPs and staff located in Charlotte, NC, Jacksonville, FL, Salem, NH, and Dublin, Ireland. Learn more at SentryOne.com.

Contact information

Megan Keller
Communications Manager
media@sentryone.com

Erik Arvidson
Matter for SentryOne
978-518-4542
sentryone@matternow.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CES Unveiled in Amsterdam to Showcase Tech for Good19.8.2019 10:00:00 EESTPress release

Consumer Technology Association (CTA): WHAT: The Consumer Technology Association (CTA)® today announced several government officials, dignitaries and industry leaders attending CES Unveiled in Amsterdam, an official CES preview event, focusing on the theme “Tech for Good.” Returning for its third year, CES Unveiled in Amsterdam will bring together executives, influential media, prominent industry influencers, and more than 100 companies (including 50+ startups) to explore the latest technology trends and innovations from the Netherlands and surrounding European countries leading up to CES® 2020. Attendees and media are able to register for CES Unveiled in Amsterdam online. WHO: Government officials and dignitaries including Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL; and Pete Hoekstra, U.S. Ambassador to the Netherlands, will share insights on emerging trends in the industry, includi

RISO Unveils VALEZUS, a New Brand for the Production-printing Market19.8.2019 09:00:00 EESTPress release

RISO KAGAKU CORPORATION (President & CEO: Akira Hayama; hereinafter “RISO”) announced today the launch of VALEZUS, a new brand of high-speed ink-jet printers for the production-printing market. RISO will start with successive rollouts worldwide of the new brand’s first product, the VALEZUS T2100, a high-speed, 320-page-per-minute (320-ppm) cut-sheet printer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190818005001/en/ 1 The new brand, VALEZUS One of RISO’s commanding strengths is the development of inks optimized for high-speed paper feeding and high-speed printing. This expertise enables RISO to deliver unique printing solutions serving the demand for high-volume printing. With technologies developed and cultivated in this field, RISO launches the VALEZUS, a fresh brand targeting the production-printing market. 2 The all-new VALEZUS T2100 VALEZUS T2100 The first product of the new brand, the VALEZUS T2100 is a high-speed

Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 15:00:00 EESTPress release

Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques

Merz Announces Key Governance Changes16.8.2019 12:26:00 EESTPress release

Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae

FINEOS lists on the Australian Securities Exchange16.8.2019 10:22:00 EESTPress release

FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis15.8.2019 23:01:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom